Psychiatria pre prax 2/2018
Výzkum nových léčiv u Alzheimerovy choroby
Research of new drugs for Alzheimer’s disease Alzheimer’s disease (AD) is the most common cause of dementia, however, the treatment AD options are limited and based on administration of cholinesterase inhibitors and/or memantine, affecting glutamatergic system. Presented review article summarizes current approaches in the research of novel agents for AD treatment; it is focused on the molecules reaching the clinical trials. The most developed direction of pharmacotherapy is focused on pathologic β-amyloid (Aβ). Several perspective studies testing monoclonal Aβ antibodies and β-secretase inhibitors are ongoing. Further, new cholinesterase inhibitors, monoamine oxidase inhibitors, anti-tau immunotherapy, agents affecting serotonin and nicotine receptors, antioxidants, and others are developed.
Keywords: Alzheimer’s disease, cholinesterase inhibitors, anti-amyloid beta immunotherapy, beta secretase inhibitors, monoamine oxidase inhibitors
